CVS Caremark to introduce pilot ePA
The CVS Caremark ePA pilot will help the company’s PBM clients in improving patients’ experience and speed access to prescription medications. It will also enable prescribers for coordinating
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).